Skip to Main content Skip to Navigation

Etude des marqueurs de la neuropathie à l’oxaliplatine

Abstract : Oxaliplatin (OXA) is an anti-cancer drug widely used in oncology, its effectiveness is recognized in first-line chemotherapy regimen in many cancers. However, its use is limited by an onset of a disabling peripheral neuropathy with a negative association with quality of life. To identify and study clinical, plasma and electrochemical markers of oxaliplatin-induced chronic neuropathy (OIPN), two pilot studies (LIPIDOXA and CANALOXA) were conducted.Patients in the LIPIDOXA study were included prior to OXA treatment and were evaluated before treatment, during treatment, and six months after discontinuation. Between May 2014 and June 2016, 35 patients were included. The onset of thermal hypoaesthesia was highlighted six months after OXA completion, revealing a neurotoxic process that extends beyond treatment. The study of plasma markers revealed, at the end of treatment, an increase of prostaglandins E2 release, a lower level of oxidative stress in patients suffering from grade-2 neuropathy as well as a decrease in the concentration of polyunsaturated triglycerides associated with a tendency in polyunsaturated free fatty acids increase. The patients in the CANALOXA study, all neuropathic, were included during treatment with OXA and evaluated once. Between April 2016 and March 2017, 36 patients were included. The values of the electrochemical conductances of the skin (ESC) were pathological for one third of patients. ESC values were well correlated with the neuropathic pain score.However, these markers are sparsely specific and seem to be of late onset. Thus, they are are not suitable for a possible monitoring of the neurological tolerance of the treatment in the current care practice. Beyond the moderate clinical and therapeutic contribution, this work strengthens the understanding of the pathophysiology of OIPN in the field of small-fiber neuropathy, the associated inflammatory processes and the disruption of lipid metabolism in the patient treated with oxaliplatin.The complementarity and similarity of this work remind us that the patient care must be global and combine various elements in which the patient must remain at the heart of the management of the OIPN. This project takes part in a dynamic of continuous improvement and the results of these pilot studies constitute the basis for further research in this field.
Document type :
Complete list of metadata

Cited literature [348 references]  Display  Hide  Download
Contributor : Abes Star :  Contact
Submitted on : Friday, June 21, 2019 - 1:25:09 PM
Last modification on : Friday, October 23, 2020 - 4:55:06 PM


Version validated by the jury (STAR)


  • HAL Id : tel-02162059, version 1


Jean-Baptiste Delmotte. Etude des marqueurs de la neuropathie à l’oxaliplatine. Pharmacologie. Université Paris-Saclay, 2018. Français. ⟨NNT : 2018SACLS600⟩. ⟨tel-02162059⟩



Record views


Files downloads